Goldman Sachs
CPRX

Goldman Sachs’s Catalyst Pharmaceutical CPRX Stock Holding History

Goldman Sachs’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$1.24M – 6626
2026
Q1 		$1.24M Buy
+50,000
New +$1.19M ﹤0.01% 4935

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's CPRX Position: Q2 2026 in Review

Goldman Sachs increased its Catalyst Pharmaceutical (CPRX) stake by 21% in Q2 2026, buying an estimated $6.18M and bringing the position to 1,194,200 shares worth $37.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2057.

Goldman Sachs first reported a position in CPRX in Q3 2014 and has held it in 47 quarters since. The position peaked at $76M in Q1 2025. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Goldman Sachs held 1,194,200 shares of Catalyst Pharmaceutical worth $37.5M as of Q2 2026.
  • Goldman Sachs bought 209,466 Catalyst Pharmaceutical shares in Q2 2026, an estimated $6.18M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2057 holding.
  • Goldman Sachs first reported a position in Catalyst Pharmaceutical in Q3 2014 and has held it in 47 quarters since.
  • Goldman Sachs's Catalyst Pharmaceutical position peaked at $76M in Q1 2025.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.